X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-20 | RNA | Hughes Steven George | Chief Medical Officer | S - Sale | $31.06 | -9,578 | 72,850 | -12% | -$297,491 | ||||||
2025-03-20 | RNA | Boyce Sarah | Pres, CEO | S - Sale | $31.06 | -31,540 | 305,871 | -9% | -$979,563 | ||||||
2025-03-20 | RNA | Flanagan W. Michael | Chief Scientific Officer | S - Sale | $31.06 | -11,780 | 80,195 | -13% | -$365,868 | ||||||
2025-03-20 | RNA | Maclean Michael F | CFO | S - Sale | $31.06 | -7,935 | 96,720 | -8% | -$246,425 | ||||||
2025-03-20 | RNA | McCarthy Teresa | CHRO | S - Sale | $31.06 | -7,778 | 97,130 | -7% | -$241,583 | ||||||
| D | 2025-03-11 | RNA | Flanagan W. Michael | Chief Scientific Officer | S - Sale+OE | $30.13 | -20,000 | 91,975 | -18% | -$602,614 | |||||
| D | 2025-03-03 | RNA | Gallagher Kathleen P. | Chief Program Officer | S - Sale+OE | $29.41 | -5,875 | 50,554 | -10% | -$172,807 | |||||
| D | 2025-02-03 | RNA | Gallagher Kathleen P. | Chief Program Officer | S - Sale+OE | $32.16 | -5,875 | 50,554 | -10% | -$188,918 | |||||
2025-01-21 | RNA | Levin Arthur A | Dir | S - Sale | $28.60 | -1,872 | 144,330 | -1% | -$53,537 | ||||||
2025-01-21 | RNA | Maclean Michael F | CFO | S - Sale | $28.59 | -3,287 | 104,655 | -3% | -$93,985 | ||||||
2025-01-21 | RNA | McCarthy Teresa | CHRO | S - Sale | $28.59 | -2,959 | 104,908 | -3% | -$84,612 | ||||||
2025-01-21 | RNA | Flanagan W. Michael | Chief Scientific Officer | S - Sale | $28.60 | -5,672 | 91,975 | -6% | -$162,192 | ||||||
2025-01-21 | RNA | Boyce Sarah | Pres, CEO | S - Sale | $28.59 | -10,397 | 337,411 | -3% | -$297,291 | ||||||
| M | 2025-01-21 | RNA | Gallagher Kathleen P. | Chief Program Officer | S - Sale | $29.53 | -9,411 | 50,554 | -16% | -$277,912 | |||||
2025-01-21 | RNA | Hughes Steven George | Chief Medical Officer | S - Sale | $28.59 | -3,947 | 82,428 | -5% | -$112,856 | ||||||
2024-12-18 | RNA | Flanagan W. Michael | CSTO | S - Sale | $32.66 | -12,742 | 72,647 | -15% | -$416,154 | ||||||
2024-12-18 | RNA | Maclean Michael F | CFO | S - Sale | $32.66 | -11,151 | 82,942 | -12% | -$364,192 | ||||||
2024-12-18 | RNA | Boyce Sarah | Pres, CEO | S - Sale | $32.66 | -31,855 | 265,308 | -11% | -$1,040,384 | ||||||
2024-12-18 | RNA | McCarthy Teresa | CHRO | S - Sale | $32.66 | -11,151 | 82,867 | -12% | -$364,192 | ||||||
| D | 2024-12-16 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $33.26 | -25,000 | 94,018 | -21% | -$831,605 | |||||
| D | 2024-12-11 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $35.77 | -24,000 | 85,389 | -22% | -$858,401 | |||||
| D | 2024-11-18 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $41.14 | -25,000 | 94,018 | -21% | -$1,028,520 | |||||
| D | 2024-11-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $42.12 | -3,323 | 146,202 | -2% | -$139,973 | |||||
| D | 2024-11-06 | RNA | Maclean Michael F | CFO | S - Sale+OE | $45.56 | -106,319 | 94,093 | -53% | -$4,843,979 | |||||
| D | 2024-10-21 | RNA | Levin Arthur A | Dir | S - Sale+OE | $46.63 | -5,000 | 146,202 | -3% | -$233,168 | |||||
| D | 2024-10-16 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $48.52 | -25,000 | 94,018 | -21% | -$1,213,010 | |||||
| D | 2024-10-07 | RNA | Thompson Tamar | Dir | S - Sale+OE | $44.98 | -30,000 | 0 | -100% | -$1,349,259 | |||||
| D | 2024-10-01 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $47.62 | -62,500 | 85,389 | -42% | -$2,976,113 | |||||
2024-09-23 | RNA | McCarthy Teresa | CHRO | S - Sale | $44.00 | -13,153 | 94,018 | -12% | -$578,737 | ||||||
2024-09-23 | RNA | Flanagan W. Michael | CSTO | S - Sale | $43.95 | -25,000 | 85,389 | -23% | -$1,098,733 | ||||||
2024-09-23 | RNA | Boyce Sarah | Pres, CEO | S - Sale | $44.00 | -32,880 | 297,163 | -10% | -$1,446,723 | ||||||
2024-09-23 | RNA | Maclean Michael F | CFO | S - Sale | $44.00 | -11,510 | 121,355 | -9% | -$506,440 | ||||||
| D | 2024-09-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.73 | -5,000 | 146,202 | -3% | -$228,658 | |||||
| D | 2024-09-11 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $40.40 | -111,394 | 60,871 | -65% | -$4,500,244 | |||||
| D | 2024-09-11 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $40.40 | -25,000 | 57,171 | -30% | -$1,010,043 | |||||
| D | 2024-08-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.19 | -5,000 | 168,702 | -3% | -$225,947 | |||||
| D | 2024-08-06 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $43.35 | -28,000 | 205,043 | -12% | -$1,213,822 | |||||
| D | 2024-07-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.01 | -5,000 | 168,702 | -3% | -$225,069 | |||||
| D | 2024-07-09 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $39.93 | -28,000 | 205,043 | -12% | -$1,118,082 | |||||
| D | 2024-06-20 | RNA | Levin Arthur A | Dir | S - Sale+OE | $37.59 | -5,000 | 168,702 | -3% | -$187,951 | |||||
2024-06-18 | RNA | McCarthy Teresa | CHRO | S - Sale | $39.13 | -9,864 | 57,171 | -15% | -$385,972 | ||||||
2024-06-18 | RNA | Maclean Michael F | CFO | S - Sale | $39.13 | -11,228 | 82,865 | -12% | -$439,345 | ||||||
2024-06-18 | RNA | Boyce Sarah | Pres, CEO | S - Sale | $39.13 | -32,074 | 205,043 | -14% | -$1,255,040 | ||||||
2024-06-18 | RNA | Flanagan W. Michael | CSTO | S - Sale | $39.13 | -10,106 | 75,765 | -12% | -$395,445 | ||||||
| D | 2024-06-12 | RNA | Maclean Michael F | CFO | S - Sale+OE | $35.72 | -104,245 | 44,093 | -70% | -$3,723,141 | |||||
| DM | 2024-06-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $38.07 | -100,000 | 168,702 | -37% | -$3,807,410 | |||||
| DM | 2024-06-12 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $38.63 | -300,000 | 112,117 | -73% | -$11,588,306 | |||||
| D | 2024-06-04 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $27.42 | -28,000 | 112,117 | -20% | -$767,780 | |||||
| D | 2024-05-20 | RNA | Levin Arthur A | Dir | S - Sale+OE | $29.90 | -5,000 | 268,702 | -2% | -$149,481 | |||||
| D | 2024-05-14 | RNA | Maclean Michael F | CFO | S - Sale+OE | $28.28 | -75,000 | 44,093 | -63% | -$2,121,045 | |||||
| D | 2024-05-07 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $25.54 | -28,000 | 112,117 | -20% | -$715,050 | |||||
| D | 2024-04-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.82 | -5,000 | 268,702 | -2% | -$114,123 | |||||
2024-04-03 | RNA | Levin Arthur A | Dir | S - Sale | $27.11 | -20,000 | 268,702 | -7% | -$542,214 | ||||||
| D | 2024-04-02 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $26.25 | -28,000 | 112,117 | -20% | -$734,919 | |||||
| D | 2024-03-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $23.97 | -5,000 | 288,702 | -2% | -$119,848 | |||||
| D | 2024-03-13 | RNA | Maclean Michael F | CFO | S - Sale+OE | $24.52 | -40,000 | 44,093 | -48% | -$980,760 | |||||
| D | 2024-03-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.03 | -27,641 | 288,702 | -9% | -$609,017 | |||||
| DM | 2024-03-08 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $21.70 | -112,000 | 112,117 | -50% | -$2,430,392 | |||||
| D | 2024-03-01 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $20.13 | -84,000 | 112,117 | -43% | -$1,691,306 | |||||
2024-01-22 | RNA | Levin Arthur A | Dir | S - Sale | $10.13 | -1,859 | 291,343 | -1% | -$18,832 | ||||||
| D | 2024-01-22 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $10.13 | -5,092 | 44,008 | -10% | -$51,582 | |||||
| D | 2024-01-22 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $10.13 | -4,129 | 35,871 | -10% | -$41,827 | |||||
| D | 2024-01-22 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $10.13 | -2,065 | 17,035 | -11% | -$20,918 | |||||
| D | 2024-01-22 | RNA | Maclean Michael F | CFO | S - Sale+OE | $10.13 | -1,616 | 16,884 | -9% | -$16,370 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |